Free Trial
NASDAQ:NVCT

Nuvectis Pharma (NVCT) Stock Price, News & Analysis

Nuvectis Pharma logo
$10.96 +0.55 (+5.28%)
As of 04:00 PM Eastern

About Nuvectis Pharma Stock (NASDAQ:NVCT)

Key Stats

Today's Range
$10.02
$11.29
50-Day Range
$6.14
$10.46
52-Week Range
$4.44
$11.80
Volume
272,867 shs
Average Volume
123,660 shs
Market Capitalization
$256.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.67
Consensus Rating
Buy

Company Overview

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Nuvectis Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
40th Percentile Overall Score

NVCT MarketRank™: 

Nuvectis Pharma scored higher than 40% of companies evaluated by MarketBeat, and ranked 565th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Nuvectis Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Nuvectis Pharma has only been the subject of 3 research reports in the past 90 days.

  • Read more about Nuvectis Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Nuvectis Pharma are expected to grow in the coming year, from ($1.01) to ($0.95) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Nuvectis Pharma is -9.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Nuvectis Pharma is -9.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Nuvectis Pharma has a P/B Ratio of 15.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Nuvectis Pharma's valuation and earnings.
  • Percentage of Shares Shorted

    13.46% of the float of Nuvectis Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Nuvectis Pharma has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Nuvectis Pharma has recently increased by 9.40%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Nuvectis Pharma does not currently pay a dividend.

  • Dividend Growth

    Nuvectis Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.46% of the float of Nuvectis Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Nuvectis Pharma has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Nuvectis Pharma has recently increased by 9.40%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    1 people have searched for NVCT on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Nuvectis Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,200,000.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    35.78% of the stock of Nuvectis Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    96.77% of the stock of Nuvectis Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Nuvectis Pharma's insider trading history.
Receive NVCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvectis Pharma and its competitors with MarketBeat's FREE daily newsletter.

NVCT Stock News Headlines

Nuvectis Pharma initiated with a Buy at Maxim
Genius investor: A “wealth window” will close June 25
Thanks to President Trump’s genius Executive Order 14179… I believe there’s a new opportunity that will be 10X BIGGER than crypto. A $10,000 investment…Could grow to $1 MILLION or more.
Nuvectis Pharma initiated with a Buy at Laidlaw
See More Headlines

NVCT Stock Analysis - Frequently Asked Questions

Nuvectis Pharma's stock was trading at $5.41 on January 1st, 2025. Since then, NVCT shares have increased by 102.6% and is now trading at $10.96.
View the best growth stocks for 2025 here
.

Nuvectis Pharma, Inc. (NASDAQ:NVCT) announced its quarterly earnings data on Tuesday, March, 4th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by $0.08.

Nuvectis Pharma (NVCT) raised $19 million in an initial public offering on Friday, February 4th 2022. The company issued 3,200,000 shares at a price of $5.00-$7.00 per share.

Top institutional shareholders of Nuvectis Pharma include Baldwin Wealth Partners LLC MA (1.53%), Oppenheimer & Co. Inc. (0.18%) and Blue Zone Wealth Advisors LLC (0.04%). Insiders that own company stock include Marlio Charles Mosseri, Enrique Poradosu, Shay Shemesh and Kenneth Hoberman.
View institutional ownership trends
.

Shares of NVCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nuvectis Pharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Invesco QQQ (QQQ), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

Last Earnings
3/04/2025
Today
4/24/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NVCT
Fax
N/A
Employees
8
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.67
High Stock Price Target
$19.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+42.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-22,260,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.70 per share
Price / Book
15.66

Miscellaneous

Free Float
12,408,000
Market Cap
$256.38 million
Optionable
Not Optionable
Beta
-0.11
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:NVCT) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners